Zenyaku Kogyo Co., Ltd.

The demand for heparin is mainly increasing due to the growing incidence of cardiovascular diseases, the expanding range of cancer risk factors such as smoking, radiation exposure, unhealthy lifestyles, and other factors, as well as the rising research and development activities by global market players throughout the forecast period from 2024 to 2030. LAS VEGAS, Sept. 4, 2024 /PRNewswire/ -- DelveInsight's Heparin Market Insights report provides the current and forecast market analysis, individual leading heparin companies' market shares, challenges, heparin market drivers, barriers, trends, and key market heparin companies in the market. Key Takeaways from the Heparin Market Report As per DelveInsight estimates, North America is anticipated to dominate the global heparin market during the forecast period. In the application segment of the heparin market, the coronary artery disease category had a significant revenue share in the Heparin market in 2023. Notable heparin companies such as Pfizer Inc., Leo Pharma A/S, Dr. Reddy's Laboratories Ltd., GSK plc., Sanofi, B. Braun Melsungen AG, Aspen Holdings, Fresenius SE & Co. KGaA, Novartis AG, Baxter, and several others, are currently operating in the heparin market. In November 2023, the FDA approved a taurolidine plus heparin (DefenCath®) catheter lock solution to reduce catheter-related bloodstream infections in patients receiving maintenance hemodialysis via a central venous catheter (CVC). In February 2022, Techdow USA Inc. announced the launch of its Heparin Sodium Injection, USP in the US market. In January 2022, the Ohio biotechnology firm Optimvia Pharmaceuticals developed a cost-effective synthetic method to produce large quantities of heparin, used to make common blood thinner, also striking a deal with the synthetic biology firm Ginkgo Bioworks to scale the process up. To read more about the latest highlights related to the heparin market, get a snapshot of the key highlights entailed in the Global Heparin Market Report Heparin Overview Heparin is a widely used anticoagulant medication that helps prevent and treat blood clots. It works by enhancing the activity of antithrombin III, a protein in the blood that inhibits blood clotting factors such as thrombin and factor Xa. Heparin is administered either intravenously or subcutaneously and is commonly used in medical settings such as during surgeries, dialysis, and for patients with certain types of heart disease. Its rapid onset and short duration of action make it particularly useful in acute settings where quick and reversible anticoagulation is needed. Despite its effectiveness, heparin therapy requires careful monitoring due to the risk of bleeding complications. One of the most significant side effects is heparin-induced thrombocytopenia (HIT), a condition where the patient's platelet count drops dramatically, which paradoxically increases the risk of thrombosis. To manage these risks, healthcare providers regularly monitor blood clotting parameters, such as activated partial thromboplastin time (aPTT), to ensure that the patient remains within a therapeutic range. In cases where heparin use is contraindicated or needs to be discontinued, alternative anticoagulants, such as low molecular weight heparins or direct oral anticoagulants, may be considered. Heparin Market Insights In 2023, North America held the largest share of the heparin market compared to other regions. This is attributed to the rising incidence of cardiovascular disorders in the area. Contributing factors include the increasing risk factors related to cardiovascular issues, strong research and development efforts, and a highly promising market for product development and launches, all of which are driving the growth of the heparin market in North America. Additionally, the growing number of heparin product launches is anticipated to drive the heparin market in North America. For instance, in February 2024, B. Braun Medical Inc. introduced its new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL), marking the fifth addition to its range of Heparin premixed bags. This launch underscores B. Braun's dedication to enhancing supply security by producing pharmaceuticals in the U.S. at its Irvine, CA facility. Given the substantial patient population in North America, the use of heparin for treatment is expected to boost market demand in the coming years. Consequently, these factors combined are projected to contribute to the growth of the heparin market in North America during the forecast period from 2024 to 2030. To know more about why North America is leading the market growth in the heparin market, get a snapshot of the Heparin Market Outlook Heparin Market Dynamics The heparin market is a critical segment within the global pharmaceutical industry, primarily driven by its essential role in anticoagulant therapy. The market dynamics are influenced by a variety of factors including technological advancements, regulatory changes, and shifts in healthcare practices. One significant driver in the heparin market is the ongoing innovation in drug delivery systems and formulations. Advances such as low molecular weight heparins (LMWHs) have improved the efficacy and safety profiles of heparin therapy, leading to increased adoption. Additionally, the development of more efficient manufacturing processes, such as recombinant heparins, has helped meet the growing demand and reduce dependency on animal sources, which can be susceptible to supply chain disruptions. Regulatory factors also play a crucial role in shaping the heparin market. Regulatory agencies, such as the FDA and the EMA, impose stringent standards on the production and quality of heparin products. These regulations are designed to ensure the safety and efficacy of heparin, which can impact market dynamics through compliance costs and potential market entry barriers for new players. Moreover, market dynamics are influenced by global healthcare trends and economic factors. Rising incidences of cardiovascular diseases and an aging population contribute to the increased demand for heparin. However, economic pressures and healthcare cost containment strategies may impact market growth. Furthermore, competition from alternative anticoagulants and biosimilars can also affect the heparin market by offering patients and healthcare providers additional options. Get a sneak peek at the heparin market dynamics @ Heparin Market Dynamics Analysis Heparin Market Assessment Heparin Market Segmentation Heparin Market Segmentation By Source: Bovine, Porcine, and Others Heparin Market Segmentation By Route of Administration: Subcutaneous and Intravenous Heparin Market Segmentation By Application: Coronary Artery Disease, Atrial Fibrillation, Venous Thromboembolism, Renal Impairment, and Others Heparin Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the heparin market are set to emerge as the trendsetter explore @ Heparin Companies Table of Contents Interested in knowing the heparin market by 2030? Click to get a snapshot of the Heparin Market Trends Related Reports Heparin-induced Thrombocytopenia Market Heparin-induced Thrombocytopenia Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key heparin-induced thrombocytopenia companies, including Sandoz, Fresenius Kabi, Hikma Pharm, Veralox Therapeutics, among others. Thrombocytopenia Market Thrombocytopenia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key thrombocytopenia companies, including Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, Millennium Pharmaceuticals, Biotest, GC Pharma, Genosco (Subsidiary of Oscotec), Rigel Pharmaceuticals, Kissei Pharmaceutical, Shionogi & Co., Ltd, Amgen, Novartis, Zenyaku Kogyo, among others. Thrombocytopenia Pipeline Thrombocytopenia Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key thrombocytopenia companies, including Takeda, Argenx, Keros Therapeutics, Principia Biopharma, Momenta Pharmaceuticals, Veralox Therapeutics, Novartis Pharmaceuticals, Pfizer, HUTCHMED, Principia Biopharma, Genosco, UCB, among others. Immune Thrombocytopenia Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key immune thrombocytopenia companies, including UCB Biopharma, Sanofi, Principia Biopharma, Argenx, Millennium Pharmaceuticals, Takeda, Biotest, GC Pharma, UCB, HanAll Biopharma, Immunovant, Momenta Pharmaceuticals, Hutchison MediPharma, Cour Pharmaceutical Development, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

Positive interim data readout from 22 patients in TREK-DX study of eblasakimab showed unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Area Severity Index (EASI) score) and 66.7% achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks, versus 14.3% of patients on placebo. On track to report topline data from two Phase 2 studies in the second half of 2024: topline interim data readout from FAST-AA, the Phase 2a, proof-of-concept study of farudodstat in alopecia areata expected in Q3 2024, and topline data from the full TREK-DX dataset expected by the end of 2024. SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities. “The unprecedented positive efficacy data we announced from the interim analysis of the TREK-DX study of eblasakimab in dupilumab-experienced AD patients in April was a fantastic achievement for ASLAN. Most of the 22 patients on eblasakimab achieved EASI-90 and vIGA of 0 or 1 after just 16 weeks of treatment - numbers that have not been seen in other biologics AD studies. These data give us strong confidence in eblasakimab’s potential to be a best-in-class treatment for AD patients even after they have had an inadequate response to dupilumab, a significant and underserved patient population with limited safe and long-term treatment options,” said Dr Carl Firth, Chief Executive Officer of ASLAN Pharmaceuticals. “Discussions with potential partners on eblasakimab are progressing well and we look forward to the upcoming topline clinical readouts from FAST-AA, the Phase 2a, proof-of-concept study of farudodstat in alopecia areata, and TREK-DX in the second half of 2024.” First quarter 2024 and recent clinical developments In February 2024, received a favorable opinion from the European Patent Office (EPO) on a composition of matter patent application for farudodstat. The EPO is acting as the International Examiner on a polymorph patent application for farudodstat, which, if granted in the national stages, will extend effective patent protection for farudodstat until at least 2043.In March 2024, announced positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of COPD. In the study, eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrations, providing further support for the potential of eblasakimab as a biologic therapy for COPD.In April 2024, announced positive interim results from the Phase 2 study of eblasakimab in moderate-to-severe atopic dermatitis (AD) adult patients previously treated with dupilumab, TREK-DX. Interim readout of 22 patients showed unprecedented efficacy data compared to prior AD studies with biologics. The primary endpoint, which is the percent change in Eczema Area Severity Index (EASI) score from baseline to Week 16, was statistically significant when compared to placebo (p=0.0059), even though the interim analysis was not powered for statistical significance due to the sample size. 73.3% (11/15) of eblasakimab-treated patients achieved a reduction in EASI score of at least 75% from baseline (EASI-75) compared to 14.3% (1/7) on placebo (p=0.0431). Of the six patients treated with eblasakimab that previously had an inadequate response to dupilumab, 66.7% achieved EASI-90 and a vIGA score of 0 or 1 after 16 weeks. Eblasakimab produced rapid and clinically meaningful itch relief versus placebo.In April, an abstract on positive translational data on eblasakimab in COPD was accepted for a late breaking poster that will be presented on May 20, 2024 at the American Thoracic Society (ATS) International Conference. Additional details from the late-breaker abstract will be shared after presentation at the conference.In May 2024, ASLAN announced the expansion of its collaboration with Zenyaku to explore the biology underlying differential effects of eblasakimab on AD patients, compared to other biologics, dupilumab and lebrikizumab. The findings may provide further insight to the recent clinical data that show some AD patients may respond to eblasakimab even after they have had an inadequate response to dupilumab. The first part of the collaboration will focus on receptor biology and kinetics to investigate the cellular and molecular basis of eblasakimab’s potential for differentiation and the work will be funded by Zenyaku.In May 2024, ASLAN hosted a virtual Key Opinion Leader (KOL) event, “Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the Potential of Eblasakimab in this Sizable New Market.” The event featured a discussion with Lisa Beck, MD from University of Rochester, Peter Lio, MD from Northwestern University, and Raj Chovatiya, MD, PhD from Rosalind Franklin University Chicago Medical School, moderated by Seth Orlow, MD, PhD from New York University, on the positive interim results from the TREK-DX study of eblasakimab and the limited treatment options currently available to patients with an inadequate response to dupilumab. A replay of the event is available here.In May 2024, ASLAN presented new data on investigator-assessed and patient-reported secondary endpoints from the interim analysis of the TREK-DX study. Discontinuation rates were lower for patients treated with eblasakimab (13%, 2/15) compared to those on placebo (43%, 3/7). Time courses for secondary endpoints demonstrated rapid onset of effect for patients treated with eblasakimab, with over half of patients achieving EASI-75 by Week 6 (8/15) and 73% (11/15) achieving EASI-75 by Week 16. These investigator assessments are further supported by patient-reported pruritus scores, which show a rapid reduction in itch, with clear separation observed as early as Week 2. Waterfall plots of individual patient responses show clear and consistent improvements in almost all patients treated with eblasakimab versus placebo. Patients with prior inadequate response to dupilumab showed mean percent change in EASI at Week 16 of 91% reduction (n=6). Topline unblinded data from the full dataset is expected at the end of 2024. First quarter and recent corporate updates In March 2024, in line with evaluating the potential use of eblasakimab as a therapy to treat COPD, ASLAN appointed respiratory experts Dr Ramaswamy Krishnan, MS MPhil PhD, Associate Professor in Emergency Medicine, Harvard Medical School, and Dr Reynold Panettieri, Jr, MD, Vice Chancellor, Translational Medicine and Science, Rutgers University, to ASLAN’s Scientific Advisory Board.In March 2024, ASLAN completed a $5.0 million registered direct offering for the purchase and sale of 5,000,000 of the Company’s American Depositary Shares (“ADSs”), each ADS representing twenty-five (25) ordinary shares, at an offering price of $1.00 per ADS. In addition, in a concurrent private placement, the Company issued unregistered warrants to purchase up to 5,000,000 ADSs with an exercise price of $1.00 per ADS. Anticipated upcoming milestones Late breaking poster presentation of positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of COPD at the American Thoracic Society International Conference 2024 on May 20, 2024 Topline interim data from the farudodstat Phase 2a study in AA expected in Q3 2024Topline data from the TREK-DX trial of eblasakimab expected at the end of 2024Selection of a development partner to advance eblasakimab into Phase 3 testing in AD and other indications First quarter 2024 financial highlights Cash used in operations for the first quarter of 2024 was $7.4 million compared to $19.3 million for the same period in 2023. The decrease was due to lower clinical development and manufacturing costs for eblasakimab studies following the TREK-AD topline data readout in July 2023.Research and development expenses were $5.9 million for the first quarter of 2024 compared to $14.1 million for the first quarter of 2023. The decrease was due to lower clinical development and manufacturing costs for eblasakimab studies following the TREK-AD topline data readout.General and administrative expenses were $3.4 million for the first quarter of 2024 compared to $4.0 million for the first quarter of 2023.Net loss attributable to stockholders for the first quarter of 2024 was $9.9 million compared to a net loss of $19.1 million for the first quarter of 2023.As of March 31, 2024, the Company had cash and cash equivalents of $18.4 million.The weighted average number of ADSs outstanding in the computation of basic loss per share for the first quarter of 2024 was 18.7 million (representing 466.8 million ordinary shares) compared to 14.8 million (representing 370.7 million ordinary shares) for the first quarter of 2023. One ADS is the equivalent of twenty-five ordinary shares. ASLAN Pharmaceuticals LimitedCONSOLIDATED BALANCE SHEETS(In US Dollars, other than shares or share data) December 31, 2023(audited) March 31, 2024(unaudited) ASSETS CURRENT ASSETS Cash and cash equivalents $21,252,058 $18,396,364 Other assets 2,877,934 2,179,230 Total current assets $24,129,992 $20,575,594 NON-CURRENT ASSETS Investments in equity instrument at financial asset at fair value through other comprehensive income 235,567 235,567 Property, plant and equipment 29,268 23,074 Right-of-use assets 229,982 153,320 Intangible assets 1,716 686 Total non-current assets 496,533 412,647 TOTAL ASSETS $24,626,525 $20,988,241 LIABILITIES AND EQUITY CURRENT LIABILITIES Trade payables $7,918,607 $9,656,228 Other payables 3,081,329 2,350,857 Lease liabilities - current 226,187 150,243 Current borrowings 1,800,387 7,165,572 Financial liabilities at fair value through profit or loss 88,394 280,646 Total current liabilities 13,114,904 19,603,546 NON-CURRENT LIABILITY Long-term borrowings 24,798,552 19,349,656 Total non-current liability 24,798,552 19,349,656 Total liabilities 37,913,456 38,953,202 EQUITY ATTRIBUTABLE TO STOCKHOLDERS OF THE COMPANY Ordinary shares 63,931,993 65,189,432 Capital surplus 243,791,693 247,775,683 Accumulated deficits (321,067,236) (330,986,695)Other reserves 56,619 56,619 Total equity attributable to stockholders of the Company (13,286,931) (17,964,961)Total equity/(capital deficiency) (13,286,931) (17,964,961)TOTAL LIABILITIES AND EQUITY/(CAPITAL DEFICIENCY) $24,626,525 $20,988,241 ASLAN Pharmaceuticals LimitedCONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(In US Dollars, other than shares or share data) For the Three MonthsEnded March 31 (unaudited) 2023 2024 OPERATING EXPENSES General and administrative expenses $(4,047,567) $(3,396,080)Research and development expenses (14,055,560) (5,895,078)Total operating expenses (18,103,127) (9,291,158)LOSS FROM OPERATIONS (18,103,127) (9,291,158)NON-OPERATING INCOME AND EXPENSES Interest income 324,547 1,740 Other income 134 69 Other gains and losses (240,875) 35,957 Finance costs (1,074,850) (666,066)Total non-operating income and expenses (991,044) (628,300)Share in losses of associated company, accounted for using equity method (11,533) — LOSS BEFORE INCOME TAX (19,105,704) (9,919,458)INCOME TAX EXPENSE (6,593) — NET LOSS FOR THE PERIOD (19,112,297) (9,919,458)TOTAL COMPREHENSIVE LOSS FOR THE PERIOD $(19,112,297) $(9,919,458)NET LOSS ATTRIBUTABLE TO: Stockholders of the Company $(19,112,297) $(9,919,458)TOTAL COMPREHENSIVE LOSS ATTRIBUTABLE TO: Stockholders of the Company $(19,112,297) $(9,919,458)LOSS PER ORDINARY SHARE Basic and diluted $(0.05) $(0.02)LOSS PER EQUIVALENT ADS Basic and diluted $(1.29) $(0.53)Weighted-average number of ordinary shares in the computation of basic loss per ordinary share 370,707,916 466,761,105 Weighted-average number of ADS in the computation of basic loss per ADS 14,828,317 18,670,444 Each ADS represents twenty-five ordinary shares About ASLAN Pharmaceuticals ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is developing eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease, and has reported positive topline data from a Phase 2b dose-ranging study in moderate-to-severe AD patients. ASLAN is currently investigating eblasakimab in dupilumab-experienced, moderate-to-severe AD patients in the TREK-DX Phase 2 trial, with topline data expected at the end of 2024. ASLAN is also developing farudodstat, a potent oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) as a potential first-in-class treatment for alopecia areata (AA) in a Phase 2a, proof-of-concept trial with an interim readout expected in Q3 2024. ASLAN has teams in San Mateo, California, and in Singapore. For additional information please visit the ASLAN website or follow ASLAN on LinkedIn. Forward looking statements This release contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of the Company. These forward-looking statements may include, but are not limited to statements regarding the Company’s business strategy and clinical development plans; statements related to the safety and efficacy of eblasakimab and farudodstat, including interim results; the Company’s plans and expected timing with respect to clinical trials, clinical trial enrollment and clinical trial results for eblasakimab and farudodstat; the potential of eblasakimab as a first-in-class treatment for atopic dermatitis and of farudodstat as a first-in-class treatment for alopecia areata; the Company’s cash runway; and expectations regarding the terms of patents and ability to obtain and maintain intellectual property protection for product candidates. The Company’s estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations, or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; risks that future clinical trial results may not be consistent with interim, initial or preliminary results or results from prior preclinical studies or clinical trials; clinical site activation rates or clinical trial enrollment rates that are lower than expected; the impact of health epidemics or pandemics, or geopolitical conflicts on the Company’s operations, research and development and clinical trials and potential disruption in the operations and business of third-party manufacturers, contract research organizations, other service providers and collaborators with whom the Company conducts business; general market conditions; changes in the competitive landscape; and the Company’s ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company’s US Securities and Exchange Commission filings and reports (Commission File No. 001- 38475), including the Company’s Annual Report on Form 20-F filed with the US Securities and Exchange Commission on April 12, 2024. All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. Estimates, projections, and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement. ASLAN Media and IR contacts Emma ThompsonSpurwing CommunicationsTel: +65 6206 7350 Email: ASLAN@spurwingcomms.comAshley R. RobinsonLifeSci Advisors, LLCTel: +1 (617) 430-7577Email: arr@lifesciadvisors.com

New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab. The findings will deepen understanding of the biology underlying the recent finding that some AD patients may respond to eblasakimab even after having an inadequate response to dupilumab. The first part of the collaboration will focus on receptor biology and kinetics to investigate the cellular and molecular basis of eblasakimab’s potential for differentiation. This work will be funded by Zenyaku. May 02, 2024 -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has signed a new research collaboration agreement with its partner, Zenyaku Kogyo Co., Ltd. (Zenyaku), to establish a framework for a succession of research projects to explore the differentiation of eblasakimab’s mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab. In previously published translational data1 from immune cells and skin biopsies of AD patients, blocking the IL-13 receptor (IL-13R) with eblasakimab appeared to be more effective at downregulating inflammatory markers than blocking the IL-4 receptor (IL-4R), the target of dupilumab, suggesting eblasakimab has the potential to be more efficient in blockade of Type 2 receptor signaling than dupilumab. Under the new research collaboration, ASLAN and Zenyaku will conduct collaborative studies that will explore the biology of the IL-13 and IL-4 receptors, including the effects of biologics eblasakimab, dupilumab and lebrikizumab on each receptor subunit. The results from this research collaboration will provide further insight into the differentiated receptor biology of targeting IL-13R versus IL-4R. The studies may also explain the long-lasting inhibition of disease severity biomarkers, such as TARC, observed after the end of the eblasakimab treatment period in earlier clinical studies2. This new agreement expands upon the commercial agreement that ASLAN signed with Zenyaku in June 2023 for the development and commercialization of eblasakimab in Japan. “Eblasakimab could be an important new treatment for the growing number of AD patients and we are pleased to expand our collaboration with ASLAN to learn more about the scientific principles underlying eblasakimab’s differentiation from other biologics by utilizing our cutting-edge research facilities. Based on the strong translational and clinical data that ASLAN has generated to date, we believe that eblasakimab has a unique mechanism of action that could provide patients with a safe, efficacious and convenient new treatment option for AD,” said Kazuhiko Haruta, Head of R&D Center, Zenyaku Kogyo. “Based on our recent positive interim data from TREK-DX, we believe eblasakimab may have the potential to be effective in AD patients with inadequate response to dupilumab and this collaboration may help us to understand the biology underlying why some patients may respond better to eblasakimab than other biologics,” said Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals. References Reddy et al EADV presentation October 2023 Cevikbas et al WCD poster presentation July 2023 Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, a key pathway driving several allergic inflammatory diseases. Eblasakimab’s unique mechanism of action enables specific blockade of the Type 2 receptor and has the potential to improve upon current biologics used to treat allergic disease. By blocking the Type 2 receptor, eblasakimab prevents signaling through both interleukin 4 (IL-4) and interleukin 13 (IL-13) – the key drivers of inflammation in AD and Type 2-driven COPD. ASLAN announced positive results from the Phase 2b TREK-AD study of eblasakimab in moderate-to-severe biologic-naïve AD patients in July 2023, and is currently investigating eblasakimab in dupilumab-experienced, moderate-to-severe AD patients in the Phase 2 trial, TREK-DX. ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is developing eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease, and has reported positive topline data from a Phase 2b dose-ranging study in moderate-to-severe AD patients. ASLAN is currently investigating eblasakimab in dupilumab-experienced, moderate-to-severe AD patients in the TREK-DX Phase 2 trial, with topline data expected at the end of 2024. ASLAN is also developing farudodstat, a potent oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) as a potential first-in-class treatment for alopecia areata (AA) in a Phase 2a, proof-of-concept trial with an interim readout expected in Q3 2024. ASLAN has teams in San Mateo, California, and in Singapore. For additional information please visit the ASLAN website or follow ASLAN on LinkedIn. The content above comes from the network. if any infringement, please contact us to modify.